



A Pfizer Company

# SAFETY DATA SHEET

Revision date: 29-Mar-2017

Version: 1.0

Page 1 of 10

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Topotecan hydrochloride injection, solution, concentrate (Hospira, Inc.)

**Trade Name:** Not applicable  
**Chemical Family:** Not determined

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as Antineoplastic

### Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Hospira UK Limited  
Horizon  
Honey Lane  
Hurley  
Maidenhead, SL6 6RJ  
United Kingdom

**Emergency telephone number:**  
**CHEMTREC (24 hours):** 1-800-424-9300  
**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**  
**International CHEMTREC (24 hours):** +1-703-527-3887

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Germ Cell Mutagenicity: Category 1B  
Reproductive Toxicity: Category 1B

### Label Elements

**Signal Word:** Danger  
**Hazard Statements:** H361 - Suspected of damaging fertility or the unborn child  
H340 - May cause genetic defects

**Precautionary Statements:** P201 - Obtain special instructions before use  
P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 2 of 10

Version: 1.0



### Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## 3. COMPOSITION / INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Hydrochloric Acid	7647-01-0	231-595-7	STOT SE 3 (H335) Skin Corr. 1A (H314) Press. Gas Acute Tox. 3 (H331)	**
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr.1A (H314)	**
Topotecan hydrochloride	119413-54-6	Not Listed	Repr. 1B (H361D) 1B (H340)	0.1

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Tartaric acid	87-69-4	201-766-0	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	*

### Additional Information:

\* Proprietary  
\*\* to adjust pH  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

## 4. FIRST AID MEASURES

### Description of First Aid Measures

#### Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

#### Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

#### Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 3 of 10

Version: 1.0

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.  
**Medical Conditions Aggravated by Exposure:** None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Designate a change area to facilitate 'good laboratory' decontamination practices. Restrict access to work area. Ground and bond all bulk transfer equipment. No open handling permitted. All operations should be fully enclosed. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical drug product Antineoplastic

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 4 of 10

Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Hydrochloric Acid

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m <sup>3</sup>
Austria OEL - MAKs	5 ppm
	8 mg/m <sup>3</sup>
Belgium OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m <sup>3</sup>
Cyprus OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Czech Republic OEL - TWA	8 mg/m <sup>3</sup>
Estonia OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m <sup>3</sup>
Germany (DFG) - MAK	2 ppm
	3.0 mg/m <sup>3</sup>
Greece OEL - TWA	5 ppm
	7 mg/m <sup>3</sup>
Hungary OEL - TWA	8 mg/m <sup>3</sup>
Ireland OEL - TWAs	5 ppm
	8 mg/m <sup>3</sup>
Italy OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Japan - OELs - Ceilings	2 ppm
	3.0 mg/m <sup>3</sup>
Latvia OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Luxembourg OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Malta OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Netherlands OEL - TWA	8 mg/m <sup>3</sup>
Poland OEL - TWA	5 mg/m <sup>3</sup>
Portugal OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Romania OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Slovakia OEL - TWA	5 ppm
	8.0 mg/m <sup>3</sup>
Slovenia OEL - TWA	5 ppm
	8 mg/m <sup>3</sup>
Spain OEL - TWA	5 ppm
	7.6 mg/m <sup>3</sup>

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 5 of 10

Version: 1.0

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Switzerland OEL -TWAs	2 ppm
	3.0 mg/m <sup>3</sup>
Vietnam OEL - TWAs	5 mg/m <sup>3</sup>

#### Sodium hydroxide

ACGIH Ceiling Threshold Limit:	2 mg/m <sup>3</sup>
Australia PEAK	2 mg/m <sup>3</sup>
Austria OEL - MAKs	2 mg/m <sup>3</sup>
Bulgaria OEL - TWA	2.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	1 mg/m <sup>3</sup>
Estonia OEL - TWA	1 mg/m <sup>3</sup>
France OEL - TWA	2 mg/m <sup>3</sup>
Greece OEL - TWA	2 mg/m <sup>3</sup>
Hungary OEL - TWA	2 mg/m <sup>3</sup>
Japan - OELs - Ceilings	2 mg/m <sup>3</sup>
Latvia OEL - TWA	0.5 mg/m <sup>3</sup>
OSHA - Final PELs - TWAs:	2 mg/m <sup>3</sup>
Poland OEL - TWA	0.5 mg/m <sup>3</sup>
Slovakia OEL - TWA	2 mg/m <sup>3</sup>
Slovenia OEL - TWA	2 mg/m <sup>3</sup>
Sweden OEL - TWAs	1 mg/m <sup>3</sup>
Switzerland OEL -TWAs	2 mg/m <sup>3</sup>

#### Tartaric acid

Germany (DFG) - MAK	2 mg/m <sup>3</sup>
---------------------	---------------------

#### Topotecan hydrochloride

Pfizer Occupational Exposure Band (OEB): OEB 5 (control exposure to <1ug/m<sup>3</sup>)

#### Exposure Controls

##### Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

##### Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

##### Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

##### Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

##### Skin:

Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

##### Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 6 of 10

Version: 1.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Lyophilized powder	<b>Color:</b>	Light yellow to Green
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture

<b>Solvent Solubility:</b>	No data available
<b>Water Solubility:</b>	No data available
<b>pH:</b>	2.6-3.2
<b>Melting/Freezing Point (°C):</b>	No data available
<b>Boiling Point (°C):</b>	No data available.
<b>Partition Coefficient: (Method, pH, Endpoint, Value)</b>	

#### Tartaric acid

No data available

#### Water for injection

No data available

#### Sodium hydroxide

No data available

#### Hydrochloric Acid

No data available

#### Topotecan hydrochloride

No data available

<b>Decomposition Temperature (°C):</b>	No data available.
--	--------------------

<b>Evaporation Rate (Gram/s):</b>	No data available
<b>Vapor Pressure (kPa):</b>	No data available
<b>Vapor Density (g/ml):</b>	No data available
<b>Relative Density:</b>	No data available
<b>Viscosity:</b>	No data available

#### Flammability:

<b>Autoignition Temperature (Solid) (°C):</b>	No data available
<b>Flammability (Solids):</b>	No data available
<b>Flash Point (Liquid) (°C):</b>	No data available
<b>Upper Explosive Limits (Liquid) (% by Vol.):</b>	No data available
<b>Lower Explosive Limits (Liquid) (% by Vol.):</b>	No data available

### 10. STABILITY AND REACTIVITY

<b>Reactivity:</b>	No data available
<b>Chemical Stability:</b>	Stable under normal conditions of use.
<b>Possibility of Hazardous Reactions</b>	
<b>Oxidizing Properties:</b>	No data available
<b>Conditions to Avoid:</b>	Fine particles (such as dust and mists) may fuel fires/explosions.
<b>Incompatible Materials:</b>	As a precautionary measure, keep away from strong oxidizers
<b>Hazardous Decomposition Products:</b>	No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 7 of 10

Version: 1.0

### 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Short Term:** Accidental ingestion may cause effects similar to those seen in clinical use.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include decreased white blood cells (leukopenia), gastrointestinal disturbances, diarrhea, fever, vasodilation, liver enzyme changes, fatigue, weakness, loss of hair, hypersensitivity reactions.

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Sodium hydroxide

Mouse IP LD50 40 mg/kg

#### Irritation / Sensitization: (Study Type, Species, Severity)

##### Sodium hydroxide

Eye Irritation Rabbit Severe  
Skin Irritation Rabbit Severe

#### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

##### Topotecan hydrochloride

Embryo / Fetal Development	Rabbit	Intravenous	0.1 mg/kg/day	LOAEL	Maternal toxicity, Embryotoxicity, Fetotoxicity
Embryo / Fetal Development	Rat	Intravenous	0.23 mg/kg/day	LOAEL	Fetotoxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Topotecan hydrochloride

*In Vitro* Mammalian Cell Mutagenicity Human Lymphocytes Positive  
*In Vitro* Mammalian Cell Mutagenicity Mouse Lymphoma Positive  
*In Vivo* Mouse Bone Marrow Positive

#### Carcinogen Status:

Not listed as a carcinogen by IARC, NTP or US OSHA.

#### Hydrochloric Acid

IARC:

Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

#### Toxicity:

#### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

##### Topotecan hydrochloride

<i>Daphnia magna</i> (Water Flea)	EC50	48 Hours	61.8 mg/L
<i>Pimephales promelas</i> (Fathead Minnow)	EC50	96 Hours	45.7 mg/L

#### Persistence and Degradability:

No data available

## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 8 of 10

Version: 1.0

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

#### Hydrochloric Acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	500 lb
California Proposition 65	5000 lb
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	231-595-7

#### Sodium hydroxide



## SAFETY DATA SHEET

Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017

Page 9 of 10

Version: 1.0

### 15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

#### Tartaric acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-766-0

#### Topotecan hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

#### Water for injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage  
Germ cell mutagenicity-Cat.1B; H340 - May cause genetic defects  
Reproductive toxicity-Cat.1B; H361 - Suspected of damaging fertility or the unborn child  
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation  
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

**Data Sources:** Publicly available toxicity information. Safety data sheets for individual ingredients.

**Reasons for Revision:** New data sheet.

**Revision date:** 29-Mar-2017

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**SAFETY DATA SHEET**

**Material Name: Topotecan hydrochloride injection, solution,  
concentrate (Hospira, Inc.)  
Revision date: 29-Mar-2017**

**Page 10 of 10**

**Version: 1.0**

---

**End of Safety Data Sheet**